Breast Cancer
CE/CME accredited
touchIN CONVERSATION
A relaxed discussion between two faculty focussed on real world clinical issues. Useful tips below will show how to navigate the activity. Join the conversation.
Close
sharing perspectives specific dees through the lens of a paediatric and an adult neurologist
Favourite
Mark as complete
Videos
Learning Objectives & Overview
Claim Credit
Toolkit
Notes
This activity is CE/CME accredited
To obtain the credit(s) from this activity, please complete this post-activity test.
Claim Credit
You may also be interested in...
touchIN CONVERSATION
sharing perspectives specific dees through the lens of a paediatric and an adult neurologist
This activity is CE/CME accredited
LAUNCH ACTIVITY
CONFERENCE HUB
Leisha A Emens, ESMO 2020 – Overall Survival Analysis from IMpassion 130 in Triple-negative Breast Cancer
GO TO HUB
CONFERENCE HUB
Stephen Johnston, ESMO 2020 – The MonarchE trial and Abemaciclib in High-risk Early Breast Cancer
GO TO HUB
touchCONGRESS
HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the SABCS 2019?
LAUNCH ACTIVITY
JOURNALS
Treatment Update for Women with Hormone Receptor-positive Advanced Breast Cancer
GO TO ARTICLE
JOURNALS
Long-term Survival after Cerebellar Metastasis Resection from Her2 3+ Locally Advanced Breast Cancer
GO TO ARTICLE
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGY
Claim Credit
touchIN CONVERSATION
sharing perspectives specific dees through the lens of a paediatric and an adult neurologist
You may also be interested in...
CONFERENCE HUB
Highlights in breast cancer – KEYNOTE-756, Checkmate-7FL, TOPION-Breast01, monarchE: Sara Tolaney, ESMO 2023
GO TO HUB
CONFERENCE HUB
Sara Tolaney, ESMO 2022: AMEERA-3 phase 2 study – Amcenestrant vs. endocrine treatment in patients with endocrine-resistant ER+/HER2− advanced breast cancer
GO TO HUB
touchPANEL DISCUSSION
Expanding options for HER2 advanced breast cancer: Taking trial data to the clinic
This activity is CE/CME accredited
LAUNCH ACTIVITY
touchCONGRESS
HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the ESMO 2019?
LAUNCH ACTIVITY
JOURNALS
Oncoplasty as the Standard of Care in Breast Cancer Surgery
GO TO ARTICLE
JOURNALS
Triple Negative Breast Cancer Pathologic Diagnosis and Current Chemotherapy Treatment Options
GO TO ARTICLE
Copied to clipboard!
accredited arrow-down-editable arrow-down arrow_left arrow-right-blue arrow-right-dark-blue arrow-right-green arrow-right-grey arrow-right-orange arrow-right-white arrow-right-blue arrow-up-orange avatar calendar chevron-down Clicky Media Logo consultant-pathologist-nurse consultant-pathologist cross cross download email exclaimation feedback filter graph-arrow interviews link mdt_icon more_dots nurse-consultant padlock patient-advocate-pathologist patient-consultant patient person pharmacist-nurse play_button play-colour-tmc play-colour Asset 1 podcast printer scenery search share single-doctor social_facebook social_googleplus social_instagram social_linkedin_alt social_linkedin_alt social_pinterest social_youtube shape-star (1) tick-blue tick-orange tick-red tick-white tick time transcript up-arrow webinar
Department Location NEW TMM Corporate Services Icons-07 NEW TMM Corporate Services Icons-08 NEW TMM Corporate Services Icons-09 NEW TMM Corporate Services Icons-10 NEW TMM Corporate Services Icons-11 NEW TMM Corporate Services Icons-12 Salary £ TMM-Corp-Site-Icons-01 TMM-Corp-Site-Icons-02 TMM-Corp-Site-Icons-03 TMM-Corp-Site-Icons-04 TMM-Corp-Site-Icons-05 TMM-Corp-Site-Icons-06 TMM-Corp-Site-Icons-07 TMM-Corp-Site-Icons-08 TMM-Corp-Site-Icons-09 TMM-Corp-Site-Icons-10 TMM-Corp-Site-Icons-11 TMM-Corp-Site-Icons-12 TMM-Corp-Site-Icons-13 TMM-Corp-Site-Icons-14 TMM-Corp-Site-Icons-15 TMM-Corp-Site-Icons-16 TMM-Corp-Site-Icons-17 TMM-Corp-Site-Icons-18 TMM-Corp-Site-Icons-19 TMM-Corp-Site-Icons-20 TMM-Corp-Site-Icons-21 TMM-Corp-Site-Icons-22 TMM-Corp-Site-Icons-23 TMM-Corp-Site-Icons-24 TMM-Corp-Site-Icons-25 TMM-Corp-Site-Icons-26 TMM-Corp-Site-Icons-27 TMM-Corp-Site-Icons-28 TMM-Corp-Site-Icons-29 TMM-Corp-Site-Icons-30 TMM-Corp-Site-Icons-31 TMM-Corp-Site-Icons-32 TMM-Corp-Site-Icons-33 TMM-Corp-Site-Icons-34 TMM-Corp-Site-Icons-35 TMM-Corp-Site-Icons-36 TMM-Corp-Site-Icons-37 TMM-Corp-Site-Icons-38 TMM-Corp-Site-Icons-39 TMM-Corp-Site-Icons-40 TMM-Corp-Site-Icons-41 TMM-Corp-Site-Icons-42 TMM-Corp-Site-Icons-43 TMM-Corp-Site-Icons-44 TMM-Corp-Site-Icons-45 TMM-Corp-Site-Icons-46 TMM-Corp-Site-Icons-47 TMM-Corp-Site-Icons-48 TMM-Corp-Site-Icons-49 TMM-Corp-Site-Icons-50 TMM-Corp-Site-Icons-51 TMM-Corp-Site-Icons-52 TMM-Corp-Site-Icons-53 TMM-Corp-Site-Icons-54 TMM-Corp-Site-Icons-55 TMM-Corp-Site-Icons-56 TMM-Corp-Site-Icons-57 TMM-Corp-Site-Icons-58 TMM-Corp-Site-Icons-59 TMM-Corp-Site-Icons-60 TMM-Corp-Site-Icons-61 TMM-Corp-Site-Icons-62 TMM-Corp-Site-Icons-63 TMM-Corp-Site-Icons-64 TMM-Corp-Site-Icons-65 TMM-Corp-Site-Icons-66 TMM-Corp-Site-Icons-67 TMM-Corp-Site-Icons-68 TMM-Corp-Site-Icons-69 TMM-Corp-Site-Icons-70 TMM-Corp-Site-Icons-71 TMM-Corp-Site-Icons-72